Showing results (601-610 of 661) with videos related to

Sort By:
Pageof 67
Journal of Hepatology|December 28, 2025
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)Virginia Genovesi, Francesca Salani, Margherita Rimini, et al.
Liver Cancer|August 20, 2021
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular CarcinomaFrancesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, et al.
Leukemia|October 18, 2024
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistanceClarissa Corinaldesi, Antony B Holmes, Gaia Martire, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatmentF Rossari, D Lavacchi, E Alimenti, et al.
Scientific Reports|November 6, 2022
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinomaMargherita Rimini, Carles Fabregat-Franco, Valentina Burgio, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|January 23, 2023
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma PatientsMargherita Rimini, Carles Fabregat-Franco, Mara Persano, et al.
JCO Precision Oncology|July 30, 2021
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesFotios Loupakis, Shruti Sharma, Madiha Derouazi, et al.
Oncology Reports|February 14, 2013
ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortiumCosmeri Rizzato, Daniele Campa, Raffaele Pezzilli, et al.
Pageof 67